CoChat

18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis

Open access

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Abstract

Background: Precisely defining the delay in onset of dementia is a particular challenge for early diagnosis. Brain [18 F] fluoro-2-deoxy-2-D-glucose (18 F-FDG) Positron Emission Tomography (PET) is a particularly interesting tool for the early diagnosis of neurodegenerative diseases, through the measurement of the cerebral glucose metabolic rate. There is currently a lack of longitudinal studies under real-life conditions, with sufficient patients, to accurately evaluate the predictive values of brain 18 F-FDG PET scans. Here, we aimed to estimate the value of brain 18 F-FDG PET for predicting the risk of dementia conversion and the risk of occurrence of a neurodegenerative pathology. Methods: Longitudinal data for a cohort of patients with no diagnosis of dementia at the time of recruitment referred by a tertiary memory clinic for brain 18 F-FDG PET were matched with (1) data from the French National Health Data System (NHDS), (2) data from the National Alzheimer Bank (NAB), and (3) lumbar puncture (LP) biomarker data. The criteria for dementia conversion were the designation, within the three years after the brain 18 F-FDG PET scan, of a long-term condition for dementia in the NHDS and a dementia stage of cognitive impairment in the NAB. The criterion for the identification of a neurodegenerative disease in the medical records was the determination of LP biomarker levels. Results: Among the 403 patients (69.9 ± 11.4 years old, 177 women) from the initial cohort with data matched with the NHDS data, 137 were matched with the NAB data, and 61 were matched with LP biomarker data. Within three years of the scan, a 18 F-FDG PET had negative predictive values of 85% for dementia conversion (according to the NHDS and NAB datasets) and 95% for the presence of LP neurodegeneration biomarkers. Conclusion: A normal brain 18 F-FDG PET scan can help rule out the risk of dementia conversion and the presence of cerebrospinal fluid (CSF) biomarker of neurodegeneration early with high certainty, allowing modifications to patient management regimens in the short term. Trial registration: Clinical Trials database (NCT04804722). March 18, 2021. Retrospectively registered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-024-01535-3

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Example of the combined visual (upper panel, axial and coronal slices of brain 18F-FDG PET images) and semiquantitative (lower panel, with hypometabolisms in green projected on axial MR slices on the left and hypometabolisms in blue on a 3D volume rendered on the right) analysis for a 65-year-old male patient (initially diagnosed with MCI); these results were consistent with Alzheimer’s disease. The final diagnosis in the National Alzheimer’s database was Alzheimer’s disease and conversion to dementia after 31.5 months
Fig. 1 Example of the combined visual (upper panel, axial and coronal slices of brain 18F-FDG PET images) and semiquantitative (lower panel, with hypometabolisms in green projected on axial MR slices on the left and hypometabolisms in blue on a 3D volume rendered on the right) analysis for a 65-year-old male patient (initially diagnosed with MCI); these results were consistent with Alzheimer’s disease. The final diagnosis in the National Alzheimer’s database was Alzheimer’s disease and conversion to dementia after 31.5 monthsCC BY · PubMed Central
Fig. 2 Flowchart for the inclusion of patients in this study. MCI, mild cognitive impairment; LP, lumbar puncture; LTC, long-term condition; NAB, National Alzheimer Bank; NHDS, National Health Data System; SCI, subjective cognitive impairment
Fig. 2 Flowchart for the inclusion of patients in this study. MCI, mild cognitive impairment; LP, lumbar puncture; LTC, long-term condition; NAB, National Alzheimer Bank; NHDS, National Health Data System; SCI, subjective cognitive impairmentCC BY · PubMed Central
Fig. 3 Dementia-free (left panel) and overall (right panel) survival curves and their 95% confidence intervals for patients with PET images demonstrating patterns supporting and not supporting a diagnosis of a neurodegenerative disease (survival according to the National Health Data System, N = 403). The red dotted lines indicate the 3 years threshold of follow-up to respond to the primary and one secondary objectives. Numbers below the respective figures represent the number of patients under follow-up without any dementia (left panel) or alive (right panel) with a PET scan not in favor of a neurodegenerative pattern (first row) and in favor of a neurodegenerative pattern (second row)
Fig. 3 Dementia-free (left panel) and overall (right panel) survival curves and their 95% confidence intervals for patients with PET images demonstrating patterns supporting and not supporting a diagnosis of a neurodegenerative disease (survival according to the National Health Data System, N = 403). The red dotted lines indicate the 3 years threshold of follow-up to respond to the primary and one secondary objectives. Numbers below the respective figures represent the number of patients under follow-up without any dementia (left panel) or alive (right panel) with a PET scan not in favor of a neurodegenerative pattern (first row) and in favor of a neurodegenerative pattern (second row)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci [Internet]. 2013 [cited 2023 Nov 27];5. http://journal.frontiersin.org/article/https://doi.org/10.3389/fnagi.2013.00017/abstract. · doi:10.3389/fnagi.2013.00017/abstract

Cited by

See all 18

Metadata

Authors
Heyer, S., Simon, M., Doyen, M., Mortada, A., Roch, V., Jeanbert, E., Thilly, N., Malaplate, C., Kearney-Schwartz, A., Jonveaux, T., Bannay, A., & Verger, A.
Affiliations
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • Inserm (FR)
Corresponding author
Verger, Antoine
Venue
Alzheimer's Research & Therapy
Published
2024-08-13
Volume
16
Issue
1
Pages
182-182
ISSN
1758-9193 (ISSN-L)
OpenAlex
W4401542515
Cited by
14
References
31
Citations by year
2026: 5 · 2025: 7 · 2024: 2
FWCI
4.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
18F-FDG PET, conversion to dementia, neurodegeneration, cerebrospinal fluid biomarkers, negative predictive value, early diagnosis, brain glucose metabolism, longitudinal follow-up, memory clinic patients, Alzheimer's disease, real-world data, cognitive impairment
MeSH terms
Aged, Aged, 80 and over, Brain, Dementia, Female, Humans, Longitudinal Studies, Male, Middle Aged, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Neurodegenerative Diseases, Fluorodeoxyglucose F18, Early Diagnosis, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis. https://app.cochat.ai/papers/10.1186/s13195-024-01535-3
The paper
Heyer, S., Simon, M., Doyen, M., Mortada, A., Roch, V., Jeanbert, E., Thilly, N., Malaplate, C., Kearney-Schwartz, A., Jonveaux, T., Bannay, A., & Verger, A. (2024). 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-024-01535-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.